ArticleAnnals of internal medicine2019

In patients ≥ 50 years with type 2 diabetes and CV disease or risk factors, dulaglutide reduced CV outcomes.

Lorraine L LipscombePubMed ↗Publisher ↗

No numbers read from the abstract.